4Petersenu DA, Endremann R. Invitro activity of BA Y12-8039,a new 8-methoxyquino lone. Chemotherapy, 1996,42 ( 3 ) :410-425.
5Stass H, Dalhoff A, Kubitza D, et al. Phamlacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy guinolone, administered to healthy subjects. Antimicrob Agents Chemother, 1998,42 ( 8 ) :2060.
6Riickdeschel G, Dalhoff A.The in vitro activity of moxifloxacin against legionella species and the effects of medium on susceptibility test results. Antimicrob Chemother, 1999,43 ( 9 ) :25-29.
7Mblondeau J. The role of PK/PD parameters to avoid selection and increase of resistance. Mutant prevention concentration. Journal of Chemotherapy,2004,16 (5) : 1-4.
8Perry CM, Or mrod D, Hurst M, et al. Gatifloxacin : a review of it use in the management of bacterial infections. Drugs, 2002,62(3) :169-207.
9[4]Moise PA,Birmingham MC,Schentag JJ.Pharmacokineticsand Metabolism of Moxifloxacin[J].Drugs of Today,2000,36(4):229-244.
